Foamix Pharmaceuticals Ltd. (FOMX) Rating Lowered to Hold at Zacks Investment Research
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. “
Several other equities research analysts have also weighed in on the stock. Guggenheim reaffirmed a “buy” rating and issued a $20.00 target price (up previously from $10.00) on shares of Foamix Pharmaceuticals in a report on Saturday, August 13th. TheStreet raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 2nd.
Foamix Pharmaceuticals (NASDAQ:FOMX) traded down 3.77% during mid-day trading on Tuesday, hitting $9.20. 86,870 shares of the company were exchanged. Foamix Pharmaceuticals has a 12-month low of $5.48 and a 12-month high of $10.40. The company has a 50 day moving average of $9.34 and a 200 day moving average of $7.55. The stock’s market cap is $282.08 million.
Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. Foamix Pharmaceuticals had a negative return on equity of 21.87% and a negative net margin of 1,201.01%. The firm earned $1.50 million during the quarter, compared to the consensus estimate of $1.10 million. On average, equities research analysts expect that Foamix Pharmaceuticals will post ($0.87) earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the company. Alpine Partners VI LLC bought a new stake in shares of Foamix Pharmaceuticals during the second quarter worth approximately $109,000. LMR Partners LLP bought a new stake in shares of Foamix Pharmaceuticals during the second quarter worth approximately $112,000. TFS Capital LLC bought a new stake in shares of Foamix Pharmaceuticals during the second quarter worth approximately $222,000. Geode Capital Management LLC raised its stake in shares of Foamix Pharmaceuticals by 13.6% in the first quarter. Geode Capital Management LLC now owns 38,243 shares of the specialty pharmaceutical company’s stock worth $249,000 after buying an additional 4,574 shares in the last quarter. Finally, Laurion Capital Management LP bought a new stake in shares of Foamix Pharmaceuticals during the second quarter worth approximately $415,000. 46.37% of the stock is currently owned by hedge funds and other institutional investors.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.
Receive News & Stock Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.